BR112021017716A2 - Método para tratar mulheres não fumantes com câncer de pulmão de células não pequenas - Google Patents

Método para tratar mulheres não fumantes com câncer de pulmão de células não pequenas

Info

Publication number
BR112021017716A2
BR112021017716A2 BR112021017716A BR112021017716A BR112021017716A2 BR 112021017716 A2 BR112021017716 A2 BR 112021017716A2 BR 112021017716 A BR112021017716 A BR 112021017716A BR 112021017716 A BR112021017716 A BR 112021017716A BR 112021017716 A2 BR112021017716 A2 BR 112021017716A2
Authority
BR
Brazil
Prior art keywords
lung cancer
small cell
cell lung
treat
smoking women
Prior art date
Application number
BR112021017716A
Other languages
English (en)
Portuguese (pt)
Inventor
Aditya Kulkami
Arun Asaithambi
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of BR112021017716A2 publication Critical patent/BR112021017716A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112021017716A 2019-03-08 2020-03-08 Método para tratar mulheres não fumantes com câncer de pulmão de células não pequenas BR112021017716A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815762P 2019-03-08 2019-03-08
PCT/US2020/021615 WO2020185640A1 (en) 2019-03-08 2020-03-08 Method for treating female non-smokers with non-small cell lung cancer

Publications (1)

Publication Number Publication Date
BR112021017716A2 true BR112021017716A2 (pt) 2021-11-16

Family

ID=72427123

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017716A BR112021017716A2 (pt) 2019-03-08 2020-03-08 Método para tratar mulheres não fumantes com câncer de pulmão de células não pequenas

Country Status (11)

Country Link
US (1) US20220168258A1 (cg-RX-API-DMAC7.html)
EP (1) EP3935043A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022525040A (cg-RX-API-DMAC7.html)
KR (1) KR20220047208A (cg-RX-API-DMAC7.html)
CN (2) CN120078760A (cg-RX-API-DMAC7.html)
AU (2) AU2020235823A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017716A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132827A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021010745A (cg-RX-API-DMAC7.html)
SG (1) SG11202109705YA (cg-RX-API-DMAC7.html)
WO (1) WO2020185640A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2249825T3 (en) * 2008-03-14 2016-01-11 Bionumerik Pharmaceuticals Inc Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
ES2476602T3 (es) * 2008-03-14 2014-07-15 Bionumerik Pharmaceuticals, Inc. Composiciones y métodos quimioprotectores
WO2009113989A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
US20170007561A1 (en) * 2014-08-08 2017-01-12 Bionumerik Pharmaceuticals, Inc. Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Also Published As

Publication number Publication date
EP3935043A4 (en) 2023-01-11
EP3935043A1 (en) 2022-01-12
CN120078760A (zh) 2025-06-03
AU2020235823A1 (en) 2021-11-04
SG11202109705YA (en) 2021-10-28
KR20220047208A (ko) 2022-04-15
JP2022525040A (ja) 2022-05-11
CN113906010A (zh) 2022-01-07
AU2025267367A1 (en) 2025-12-04
JP2025081338A (ja) 2025-05-27
US20220168258A1 (en) 2022-06-02
MX2021010745A (es) 2021-12-15
WO2020185640A1 (en) 2020-09-17
CA3132827A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
Locatelli et al. Clofarabine, cyclophosphamide and etoposide as single‐course re‐induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia
ZA202307538B (en) Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
BR112022000231A2 (pt) Novos métodos
BR112022019085A2 (pt) Uso de agentes para tratamento de condições respiratórias
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
AR119158A1 (es) Tratamientos de angioedema hereditario
BR112023021131A2 (pt) Tratamento de tremor essencial
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
BR112022002202A2 (pt) Métodos de tratar doença de fabry em pacientes tendo uma mutação no gene gla
Pujol et al. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer
BRPI0606774A2 (pt) método para o tratamento de um paciente humano que tem carcinoma de célula renal e uso de il-2
BR112023002089A2 (pt) Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2020033838A3 (en) Treatment of egfr-mutant cancer
BR112016028641A2 (pt) ?método para tratar câncer?
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
AU2021339851A8 (en) Method of treating amyloidosis
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
WO2021007314A3 (en) Treatment of cancer
BR112023025863A2 (pt) Métodos para tratar doença pulmonar obstrutiva crônica (dpoc), para reduzir a frequência de exacerbações moderadas a graves em um paciente com dpoc, para tratar ou prevenir dpoc, para manter e/ou melhorar a função pulmonar, para melhorar a contagem de linha de base de eosinófilos no sangue, kit, antagonistas de st2 e anticorpo anti-st2
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
JOP20230219A1 (ar) نظام جرعات سوتوراسيب
Tomková et al. Phytomenadione pre‐treatment in EGFR inhibitor‐induced folliculitis
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
BR112023017999A2 (pt) Obicetrapibe para tratamento de demências

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: LANTERN PHARMA INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]